185 related articles for article (PubMed ID: 8706029)
1. An uncertain role for p53 gene alterations in human prostate cancers.
Brooks JD; Bova GS; Ewing CM; Piantadosi S; Carter BS; Robinson JC; Epstein JI; Isaacs WB
Cancer Res; 1996 Aug; 56(16):3814-22. PubMed ID: 8706029
[TBL] [Abstract][Full Text] [Related]
2. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss.
Dong JT; Suzuki H; Pin SS; Bova GS; Schalken JA; Isaacs WB; Barrett JC; Isaacs JT
Cancer Res; 1996 Oct; 56(19):4387-90. PubMed ID: 8813131
[TBL] [Abstract][Full Text] [Related]
4. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.
Wagata T; Shibagaki I; Imamura M; Shimada Y; Toguchida J; Yandell DW; Ikenaga M; Tobe T; Ishizaki K
Cancer Res; 1993 Feb; 53(4):846-50. PubMed ID: 8094033
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
[TBL] [Abstract][Full Text] [Related]
6. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
7. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer.
Massenkeil G; Oberhuber H; Hailemariam S; Sulser T; Diener PA; Bannwart F; Schäfer R; Schwarte-Waldhoff I
Anticancer Res; 1994; 14(6B):2785-90. PubMed ID: 7872719
[TBL] [Abstract][Full Text] [Related]
8. p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma.
Prendergast NJ; Atkins MR; Schatte EC; Paulson DF; Walther PJ
J Urol; 1996 May; 155(5):1685-92. PubMed ID: 8627854
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer.
Dalbagni G; Presti JC; Reuter VE; Zhang ZF; Sarkis AS; Fair WR; Cordon-Cardo C
Diagn Mol Pathol; 1993 Mar; 2(1):4-13. PubMed ID: 7904525
[TBL] [Abstract][Full Text] [Related]
10. Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer.
Watatani M; Yoshida T; Kuroda K; Ieda S; Yasutomi M
Cancer; 1996 Apr; 77(8 Suppl):1688-93. PubMed ID: 8608563
[TBL] [Abstract][Full Text] [Related]
11. p53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 and 17p allelic loss in colorectal carcinoma.
Cunningham J; Lust JA; Schaid DJ; Bren GD; Carpenter HA; Rizza E; Kovach JS; Thibodeau SN
Cancer Res; 1992 Apr; 52(7):1974-80. PubMed ID: 1551126
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas.
Yamaguchi T; Toguchida J; Wadayama B; Kanoe H; Nakayama T; Ishizaki K; Ikenaga M; Kotoura Y; Sasaki MS
Anticancer Res; 1996; 16(4A):2009-15. PubMed ID: 8712735
[TBL] [Abstract][Full Text] [Related]
14. Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors.
Tsao SW; Mok CH; Oike K; Muto M; Goodman HM; Sheets EE; Berkowitz RS; Knapp RC; Lau CC
Anticancer Res; 1991; 11(6):1975-82. PubMed ID: 1776830
[TBL] [Abstract][Full Text] [Related]
15. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
16. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases.
Stapleton AM; Timme TL; Gousse AE; Li QF; Tobon AA; Kattan MW; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1997 Aug; 3(8):1389-97. PubMed ID: 9815823
[TBL] [Abstract][Full Text] [Related]
17. p53 protein and gene alterations in pathological stage C prostate carcinoma.
Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ
J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335
[TBL] [Abstract][Full Text] [Related]
18. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
19. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers.
Suzuki H; Komiya A; Emi M; Kuramochi H; Shiraishi T; Yatani R; Shimazaki J
Genes Chromosomes Cancer; 1996 Dec; 17(4):225-33. PubMed ID: 8946204
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma.
Frank TS; Bartos RE; Haefner HK; Roberts JA; Wilson MD; Hubbell GP
Mod Pathol; 1994 Jan; 7(1):3-8. PubMed ID: 7909153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
